Weight Management for Obesity and Kidney Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using more than the starting dose of certain medications like semaglutide, liraglutide, or dulaglutide.
What data supports the effectiveness of the drug Semaglutide for weight management in patients with obesity and kidney disease?
Is the treatment safe for humans?
Semaglutide, marketed under names like Rybelsus, Ozempic, and Wegovy, has been shown to be safe in humans, including those with type 2 diabetes and chronic kidney disease. It is generally well-tolerated and has a good safety profile, with benefits such as weight loss and cardiovascular protection.26789
How is the drug Semaglutide unique for treating obesity and kidney disease?
What is the purpose of this trial?
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Research Team
Kristin K Clemens, MD, MSc
Principal Investigator
St. Joseph's Health Care London
Louise Moist
Principal Investigator
London Health Sciences Centre
Eligibility Criteria
This trial is for individuals with obesity and high-risk chronic kidney disease (CKD) or those on dialysis, aiming to lose weight for a kidney transplant. Participants must be seeking to manage their weight and willing to engage in a virtual program.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Vanguard Phase
Feasibility study to ensure recruitment and process inclusivity, and assess program acceptability
Treatment
Participants receive either usual care or a virtual weight management program with semaglutide and coaching
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Semaglutide
- Virtual Weight Management Coaching
Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications:
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Obesity
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Western University, Canada
Lead Sponsor
Lawson Health Research Institute
Collaborator
Unity Health Toronto
Collaborator
Queen Elizabeth II Health Sciences Centre
Collaborator
St. Michael's Hospital (Toronto, Canada)
Collaborator
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Collaborator
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborator
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Collaborator